Ovarian Cancer Drugs Market Report 2025

The ovarian cancer drugs market size has grown rapidly in recent years. It will grow from $5.15 billion in 2024 to $5.83 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to rising incidences of ovarian cancer, a rise of new medications and therapies, an increase in government initiatives for ovarian cancer treatment and increased healthcare expenditure.

The ovarian cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $10.1 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing geriatric population and an increase in pharmaceutical R&D expenditure. Major trends in the forecast period include launching antibody-drug conjugates, partnerships and collaborations to improve revenues and product offerings, and focus on implanted drug factories for ovarian cancer.

The forecast of 14.7% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of ovarian cancer drugs sourced from Switzerland and Denmark, thereby limiting access to life-saving therapies and raising gynecologic oncology expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of ovarian cancer is a key driver of growth in the ovarian cancer drugs market. Ovarian cancer ranks as the eighth most commonly diagnosed cancer in women and the 18th most prevalent cancer globally. In 2023, as reported by the American Cancer Society in their Ovarian Cancer Statistics, an estimated 19,710 new cases of cancer and 13,270 related deaths were anticipated in the USA alone. This rise in ovarian cancer incidence worldwide contributes significantly to the expansion of the ovarian cancer drugs market.

Government initiatives and funding for ovarian cancer are expected to significantly drive the growth of the ovarian cancer drugs market in the future. These initiatives provide financial support to selected entities with projects aimed at enhancing public services and the economy. Government aid in ovarian cancer research plays a crucial role in improving the quality of life and survival rates for patients with this disease. For example, in July 2022, the Ovarian Cancer Research Alliance, Inc., a US-based nonprofit organization, announced an additional allocation of $2 million for both Johanna’s Law and the Ovarian Cancer Control Initiative, representing a substantial increase from the $500,000 increments approved for FY22. As a result, government initiatives and funding for ovarian cancer are driving growth in the ovarian cancer drugs market.

Major companies in the ovarian cancer drug market are concentrating on developing innovative solutions, such as treatments for breast and ovarian cancer, to enhance therapeutic efficacy and improve patient outcomes. Treatments for breast and ovarian cancer encompass various medical approaches aimed at managing and combating these distinct types of malignancies that affect women. For example, in June 2024, Shorla Oncology, an Ireland-based pharmaceutical company, received FDA approval for Tepylute, a new ready-to-dilute formulation of thiotepa designed for the treatment of breast and ovarian cancers. This liquid formulation simplifies administration by removing the need for complex reconstitution, ensuring consistent dosing accuracy. The recommended dosage ranges from 0.3 mg/kg to 0.4 mg/kg, administered intravenously every 1 to 4 weeks, beginning with higher initial doses followed by maintenance adjustments based on blood counts.

Major players in the ovarian cancer drug market are strategically focusing on producing innovative drugs, including antibody-drug conjugates, to drive market revenues. Antibody-drug conjugates (ADCs) represent a biopharmaceutical drug category that combines a monoclonal antibody (mAb) with a cytotoxic drug through a chemical linker. For instance, in November 2022, the US-based biotechnology company ImmunoGen, Inc. introduced Mirvetuximab soravtansine-gynx. This drug targets the overexpressed FRα protein on the surface of many cancer cells, including ovarian cancer cells. The antibody delivers the microtubule inhibitor soravtansine to the cancer cells, disrupting their mitosis and causing cell death. This ADC shows promise as a new treatment for patients with folate receptor alpha-positive, platinum-resistant ovarian cancer. It represents the first ADC approved for this type of cancer and has demonstrated positive outcomes in clinical trials.

In February 2024, AbbVie, an American pharmaceutical company, acquired ImmunoGen for $10.1 billion. This acquisition is intended to substantially enhance AbbVie’s oncology portfolio by incorporating ImmunoGen's flagship therapy, ELAHERE, an antibody-drug conjugate approved for the treatment of platinum-resistant ovarian cancer. ImmunoGen is a U.S.-based biotechnology company that focuses on developing antibody-drug conjugates (ADCs) specifically for ovarian cancer treatment.

Major companies operating in the ovarian cancer drugs market include AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer, Inc., Novartis AG, Pharma Mar SA, Vivesto, BDR Pharmaceutical, GLS Pharma, Eisai Co., Ltd., Denovo Biopharma, Jiangsu Hengrui Medicine, BeiGene, Innovent Biologics, Zai Lab, EUSA Pharma, Recordati, NEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, Msd Sanofi, Gilead Sciences, Johnson & Johnson, Merck & Co, AbbVie Inc, Aa Pharma In, Aaladin Superior Cleaning Systems Ltd, Accel Pharma Inc, EMS Pharma, Eurofarma, Neo Química, Mantecorp Farmasa, Abbott Laboratories Bayer, Laboratorio Elea Phoenix, Laboratorios Ac Farma, Teva, Monte Verde, Gador, Spimaco, Tabuk Pharmaceuticals, Jamjoom Pharma, Abcon International L.L.C., Adcan Pharma, Regal Pharmaceuticals Limited.

North America was the largest region in the ovarian cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global ovarian cancer drugs market share during the forecast period. The regions covered in the ovarian cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ovarian cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The ovarian cancer drugs market research report is one of a series of new reports that provides ovarian cancer drugs market statistics, including ovarian cancer drugs industry global market size, regional shares, competitors with an ovarian cancer drugs market share, detailed ovarian cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer drugs industry. This ovarian cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ovarian cancer drugs are pharmaceuticals specifically designed for the treatment of ovarian cancer, a condition arising from abnormal cell growth in the ovaries. This sector encompasses establishments engaged in the production of drugs utilized in ovarian cancer treatment through chemotherapy, radiation, and surgery. Notable examples of ovarian cancer drugs include Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide), among others.

Ovarian cancer drugs target different types of tumors, namely epithelial ovarian cancer, germ cell ovarian cancer, and stromal cell ovarian cancer. Epithelial ovarian cancer is the most prevalent type, accounting for 90% of ovarian tumors. This form originates in the epithelial layer that covers the ovary. The diverse categories of drugs for ovarian cancer treatment include alkylating agents, mitotic inhibitors, VEGF/VEGF inhibitors, PARP inhibitors, among others. These drugs are distributed through various channels such as hospital pharmacies, drug stores, and others.

The ovarian cancer drugs market consists of sales of Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, and Platinol (Cisplatin). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.